ALISO VIEJO, Calif.--(BUSINESS WIRE)--AqueSys, Inc., the developer of minimally invasive stent technology for the treatment of glaucoma, announced today that the company received a Class 3 Medical Device License for the XEN Gel Stent from Health Canada, allowing the device to be sold in Canada. AqueSys has chosen Salient Medical Solutions as the Canadian distributor and commercialization is expected to begin immediately. The XEN Gel Stent is intended to reduce intraocular pressure (IOP) in patients with primary open angle glaucoma where previous medical treatments have failed.
Help employers find you! Check out all the jobs and post your resume.
